ImmunityBio, Inc.

NasdaqGS:IBRX Stock Report

Market Cap: US$8.2b

ImmunityBio Management

Management criteria checks 2/4

ImmunityBio's CEO is Rich Adcock, appointed in Oct 2020, has a tenure of 5.83 years. total yearly compensation is $12.72M, comprised of 6.5% salary and 93.5% bonuses, including company stock and options. directly owns 0.053% of the company’s shares, worth $4.33M. The average tenure of the management team and the board of directors is 5.1 years and 5.8 years respectively.

Key information

Rich Adcock

Chief executive officer

US$12.7m

Total compensation

CEO salary percentage6.54%
CEO tenure5.8yrs
CEO ownership0.05%
Management average tenure5.1yrs
Board average tenure5.8yrs

Recent management updates

Recent updates

Narrative Update • Jul 24

IBRX: FDA Review Timeline For Bladder Cancer Will Drive Future Upside

Analysts have reset their price target on ImmunityBio from $23 to $15. This reflects updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions.
Seeking Alpha • Jul 16

ImmunityBio: Intriguing Progress, If Not (Yet) Commercially - Still A Hold

Summary ImmunityBio (IBRX) remains rated Hold as its $8bn+ valuation relies on future clinical and regulatory milestones, not current fundamentals. Anktiva's clinical data in NMIBC and NSCLC is encouraging, but competition is intense and label expansion is critical for long-term upside. Q1 2026 revenues reached $44.2m, but heavy operating losses and cash burn highlight the need for significant revenue ramp or new funding. Key risks include 'key man' dependence on Dr. Soon Shiong, lack of 2026 guidance, and the need for US approvals beyond NMIBC. Read the full article on Seeking Alpha
Narrative Update • Jul 10

IBRX: Saudi Rollout And FDA Label Review Will Drive Future Upside

Analysts have raised their ImmunityBio price target from $11.00 to $12.00, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E as the key drivers of the revision. What’s in the News for ImmunityBio ImmunityBio shares recently reached a 3 month high, with investors focused on July catalysts including the commercial rollout of Anktiva in Saudi Arabia and upcoming updates on second quarter sales performance.
Narrative Update • Jun 26

IBRX: Potential Index Inclusion Will Support Cancer Franchise Expansion

Analysts have lowered their ImmunityBio price target slightly from $13.50 to $13.00 as they refresh assumptions around discount rates, revenue growth, margins, and future P/E expectations. What’s in the News for ImmunityBio Retail traders are speculating that ImmunityBio stock could shift from the Russell 2000 to the Russell 1000 based on a cutoff around US$5.7b, with some traders expecting potential index fund buying and changes in volatility if inclusion occurs, according to recent Stocktwits sentiment data and after hours trading moves.
Analysis Article • May 11

Here's What Analysts Are Forecasting For ImmunityBio, Inc. (NASDAQ:IBRX) After Its First-Quarter Results

Shareholders of ImmunityBio, Inc. ( NASDAQ:IBRX ) will be pleased this week, given that the stock price is up 15% to...
New Narrative • Apr 01

Expanded Immunotherapy Platform And Automation Will Transform Long Term Earnings Power

Catalysts About ImmunityBio ImmunityBio is a clinical stage immunotherapy company focused on using its IL-15 based ANKTIVA platform, natural killer cell therapies, and DNA vaccine vectors to treat cancer and immune related conditions. What are the underlying business or industry changes driving this perspective?
New Narrative • Mar 18

Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential

Catalysts About ImmunityBio ImmunityBio develops immunotherapy treatments that use cytokines, cell therapies, and DNA vaccines to target cancer and immune dysfunction. What are the underlying business or industry changes driving this perspective?
New Narrative • Mar 04

Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects

Catalysts About ImmunityBio ImmunityBio is a commercial stage immunotherapy company focused on ANKTIVA and a broader platform of cytokine, cell therapy, and DNA vaccine candidates for oncology and immune related conditions. What are the underlying business or industry changes driving this perspective?
Seeking Alpha • Apr 29

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish

Summary ImmunityBio, Inc.'s stock has significantly declined despite my previous "Buy" ratings, primarily due to a $100m fundraising and market selloff in December. Founder Dr. Patrick Soon-Shiong's vision for Anktiva as a groundbreaking cancer therapy remains strong, with promising data and potential label expansions in multiple oncology fields. Short-term concerns include high cash burn, premium pricing, and BCG shortages, which may lead to a stock selloff after Q1 earnings. Long-term optimism persists for IBRX stock due to Anktiva's "best-in-class" data and potential for significant market cap growth, despite immediate financial challenges. Read the full article on Seeking Alpha
Seeking Alpha • Mar 07

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum

Summary ImmunityBio faces significant operational risks due to reliance on international BCG supplies and competition from Adstiladrin in NMIBC treatment. Financially, ImmunityBio struggles with high cash burn, limited cash runway, and substantial debt, despite backing from billionaire founder Dr. Patrick Soon-Shiong. Anktiva's market adoption is uncertain beyond NMIBC, with potential hurdles in expanding to other indications like NSCLC, ovarian cancer, and TNBC. Despite Anktiva's potential, IBRX remains a "sell" due to operational, competitive, and financial challenges outweighing its prospects. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Rich Adcock's remuneration changed compared to ImmunityBio's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-US$992m

Mar 31 2026n/an/a

-US$855m

Dec 31 2025US$13mUS$832k

-US$351m

Sep 30 2025n/an/a

-US$349m

Jun 30 2025n/an/a

-US$367m

Mar 31 2025n/an/a

-US$409m

Dec 31 2024US$11mUS$802k

-US$414m

Sep 30 2024n/an/a

-US$588m

Jun 30 2024n/an/a

-US$598m

Mar 31 2024n/an/a

-US$601m

Dec 31 2023US$1mUS$796k

-US$583m

Sep 30 2023n/an/a

-US$458m

Jun 30 2023n/an/a

-US$473m

Mar 31 2023n/an/a

-US$430m

Dec 31 2022US$4mUS$791k

-US$417m

Sep 30 2022n/an/a

-US$400m

Jun 30 2022n/an/a

-US$376m

Mar 31 2022n/an/a

-US$370m

Dec 31 2021US$29mUS$765k

-US$347m

Sep 30 2021n/an/a

-US$323m

Jun 30 2021n/an/a

-US$301m

Mar 31 2021n/an/a

-US$264m

Dec 31 2020US$843kUS$141k

-US$222m

Compensation vs Market: Rich's total compensation ($USD12.72M) is above average for companies of similar size in the US market ($USD8.22M).

Compensation vs Earnings: Rich's compensation has increased whilst the company is unprofitable.

CEO

Rich Adcock (57 yo)

5.8yrs
Tenure
US$12,716,953
Compensation

Mr. Richard Gerald Adcock, also known as Rich, has been the President of ImmunityBio, Inc. since March 05, 2021 and serves as its Director since March 29, 2021. He has been the Chief Executive Officer of I...

Leadership Team

NamePositionTenureCompensationOwnership
Patrick Soon-Shiong
Founder11.8yrsUS$12.29m27.5%
$ 2.3b
Richard Adcock
President5.8yrsUS$12.72m0.053%
$ 4.3m
David Sachs
Chief Financial Officer7.1yrsUS$4.24m0.028%
$ 2.3m
Regan Lauer
Chief Accounting Officer4.8yrsUS$745.31k0.011%
$ 895.4k
Barry Simon
Chief Corporate Affairs Officer & Director5.4yrsno data0.26%
$ 21.7m
Enrique Diloné
Chief Technology Officer3.6yrsno datano data
Sarah Singleton
Chief Communications Officer & Head of Patient Advocacy6.4yrsno datano data
Emily Arison
Senior Vice President of Human Resources5.1yrsno datano data
Leonard Sender
Chief Medical Officer of Liquid Tumors & Cell Therapy1.5yrsno datano data
Sandeep Reddy
Chief Medical Officer6yrsno datano data
Hans Klingemann
Chief Science Officer of Cellularno datano datano data
Manju Saxena
Senior VP of Product Development & Cell Therapy Program2.6yrsno datano data
5.1yrs
Average Tenure
59yo
Average Age

Experienced Management: IBRX's management team is seasoned and experienced (5.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Patrick Soon-Shiong
Founder11.8yrsUS$12.29m27.5%
$ 2.3b
Richard Adcock
President5.4yrsUS$12.72m0.053%
$ 4.3m
Barry Simon
Chief Corporate Affairs Officer & Director19.6yrsno data0.26%
$ 21.7m
Christobel Selecky
Independent Director6yrsUS$477.28kno data
Wesley Clark
Independent Director5.5yrsUS$470.59k0.00075%
$ 61.4k
Bruce Wendel
Independent Directorless than a yearUS$302.74kno data
Michael Blaszyk
Independent Director11.1yrsUS$513.38k0.025%
$ 2.1m
Jim Kim
Vice Chairmanno datano datano data
Cheryl Cohen
Lead Independent Director7.2yrsUS$514.19k0.012%
$ 969.2k
Linda Maxwell
Independent Director5.4yrsUS$489.19k0%
$ 0
5.8yrs
Average Tenure
69yo
Average Age

Experienced Board: IBRX's board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/19 01:32
End of Day Share Price 2026/08/18 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ImmunityBio, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Suranjit MukherjeeBTIG
Justin ZelinBTIG
Jason KolbertD. Boral Capital LLC.